trial · primary record
Copper Cu 64-DOTA-Trastuzumab
HER2 Positive Breast Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2027-08-26 |
| Primary endpoint | Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy). |
| Registry ID | NCT02827877 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:32.348Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02827877
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.